These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18340113)

  • 1. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
    Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
    Temmink OH; Hoebe EK; Fukushima M; Peters GJ
    Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
    Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
    Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
    Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
    Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma.
    Cabal-Hierro L; O'Dwyer PJ
    Mol Cancer Res; 2017 Apr; 15(4):395-404. PubMed ID: 28087739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
    Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
    Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L
    Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
    Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
    Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-related Molecular Mechanism of Sensitizing Colon Cancer Cells to Camptothecin Analog SN38.
    Nikolova B; Semkova S; Tsoneva I; Stoyanova E; Lefterov P; Lazarova D; Zhelev Z; Aoki I; Higashi T; Bakalova R
    Anticancer Res; 2020 Sep; 40(9):5159-5170. PubMed ID: 32878804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
    Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
    Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells.
    Yun HJ; Kim SY; Kwon YY; Kim CH; Kang CM; Kim EJ
    Cancer Biol Ther; 2010 Aug; 10(4):354-61. PubMed ID: 20534983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.